1 / 37

Osteonecrosis of the Hip: Diagnosis and Management of Ficat I and II

Osteonecrosis of the Hip: Diagnosis and Management of Ficat I and II. Natasha Holder, MD, MSc . PGY-1. Overview. Osteonecrosis of the femoral head Etiology, Pathogenesis Clinical Presentation Diagnosis Classification of AVN Management of Stage I and Stage II Non-Operative

dermot
Télécharger la présentation

Osteonecrosis of the Hip: Diagnosis and Management of Ficat I and II

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Osteonecrosis of the Hip: Diagnosis and Management ofFicat I and II Natasha Holder, MD, MSc. PGY-1

  2. Overview • Osteonecrosis of the femoral head • Etiology, Pathogenesis • Clinical Presentation • Diagnosis • Classification of AVN • Management of Stage I and Stage II • Non-Operative • Core Decompression • Bone Grafting • Osteotomy

  3. Osteonecrosis of the Femoral Head • AKA avascular necrosis or aseptic necrosis • Disruption of the blood flow to the femoral head (traumatic or nontraumatic) • Commonly affects patients between 20 and 50 years of age • Ultimate goal of treatment of ON of the hip is preservation of the femoral head

  4. Risk Factors for Osteonecrosis • Trauma • Corticosteroid use • Alcohol abuse • Smoking • Sickle cell anemia • Coagulopathies • Systemic lupus erythematosus • Hypercholesterolemia • Organ Transplantation JAAOS, 1999:250-261

  5. Risk Factors for Osteonecrosis • Gaucher Disease • Caisson Disease • Radiation Therapy • Arterial disorders • Intramedullary hemorrhages • Chronic Pancreatitis • Hypertriglyceridemia • HIV JAAOS, 1999:250-261

  6. Clinical Presentation • Early in the disease process, the condition is painless • Chief complaint is pain • Localized to the groin area, but it may also manifest in the ipsilateral buttock, knee, or greater trochanteric region. • Painful symptoms are usually exacerbated with weight bearing but are relieved by rest

  7. Diagnosis • History • High index of suspicion • Risk factors • Groin pain, night pain • Physical Exam • Pain on internal rotation • Pain with active and passive ROM • Decreased ROM • Antalgic gait • Examine the contralateral hip

  8. Diagnosis • Laboratory tests • R/O systemic disease, coagulopathies • Radiological Tests • Plain film - AP and Frog leg lateral • Cysts, sclerosis or a crescent sign • Crescent sign results from subchondral collapse of the necrotic segment • MRI – Diagnostic Standard • Bone Scan • Special Tests • Bone marrow pressure, venography, biopsy

  9. Ficat and Arlet Classification

  10. Treatment of Osteonecrosis • Non-operative Treatment • Operative Treatment • Core decompression • Non-vascularized bone-grafting • Vascularized bone-grafting • Osteotomy • Non-operative Treatment • Operative Treatment • Core decompression • Non-vascularized bone-grafting • Vascularized bone-grafting • Osteotomy • Limited Femoral Resurfacing Arthroplasty • Total Hip Arthroplasty

  11. Non-Operative Treatment • Restricted weight bearing is NOT an treatment option except in small, asymptomatic lesions outside the weight bearing area • Meta analysis of outcomes of protected weight bearing in 819 patients demonstrated a failure rate >80 % at a mean of 34 months (Mont et al. ClinOrthRelat Res, 1996:169-78)

  12. Non-Operative Treatment • Pharmacological agents: lipid-lowering drugs, anticoagulants, vasodilators and bisphoshonates • Prichett et al. report at a mean of 7.5 years, ON of the femoral head has developed in only 1% of 284 patients who were taking high dose steroids and a statin. (ClinOrthop 2001; 386:173-8)

  13. Non-Operative Treatment • Glueck et al. used enoxaparin (60mg/day for 12 weeks) to treat patients with thrombophillic or hypofribinolytic disorders in early stages of ON • At 2 years, 89% (31/35 hips) had not required surgery and remained at the Ficat I or II stage (ClinOrthRelat Res, 2005:164-70)

  14. Non-Operative Treatment • Bisphosonates inhibit osteoclast activity and thus curtail bone reabsorption • Agarwala et al. first reported the efficacy of bisphosphonates. Showed an improvement in Harris hip scores, retarded progression of of the disease and reduced rate of collapse (Rhemat. 2005:353-59)

  15. Non-Operative Treatment • Agarwala et al. • prospective study • 395 hips treated with 10 mg alendronate/day • F/U 1-8 years • 92% had a satisfactory result (no surgical intervention) • Patients had improvement in clinical function, a reduction in rate of collapse and a decreased requirement for THA • Improvement is marked if treatment is begun in the pre-collapse stages

  16. Core Decompression • Goal: to decompress the femoral head and reduce the intraosseous pressure • No general agreement on indications or technique • Substantial differences in success rates reported • poor staging of patient pathology • recurrent insults depending on pathology • variations in techniques

  17. Core Decompression • Originally employed by Ficat and Arlet to obtain histological specimens • Decompression reduced bone marrow pressure allowing restoration of blood flow • Stulberg et al. (ClinOrthop 1991, 268:140-51) • Prospective, randomised study, 55 hips • 70% success by Harris Hip score with Ficat I, II, or III stage • Koo et al. (JBJS 1995, 77:870-74) • Randomised control trial, 37 hips • Operative Group: 72% progression and 72% of those that progressed required THA • Non-Operative group: 79% progression and 68% required THA

  18. Core Decompression • Retrospective studies have shown that results of core decompression were substantially worse when there had been collapse of the femoral head preoperatively • Smith et al. (JBJS 1995, 77:674-80) • Retrospective review of 114 hips • Decrease in success rate if the crescent sign had been present • 80% success rate for Ficat I, 20% If crescent sign was present, 0% femoral head collapse

  19. Vascularized Bone Grafting • Rationale: • Decompress the femoral head • Removal necrotic bone • Replacement with autogenouscancellous bone • Support the subchondral bone with a strong and viable bone strut • Revascularization the femoral head

  20. Vascularized Bone Grafting

  21. Vascularized Bone Grafting Urbaniak et al. (JBJS 1995; 77:681-94) • 103 hips, Mean F/U 7 years • Best results were seen in those with small or medium precollapse lesions. • 11% (2/19) of pre-collapse group were converted to THA • 23% (5/22) of post-collapse group were converted to THA • 39% (24/62) of advanced lesion group were converted to THA Berend et al. (JBJS 2003; 85:987-93) • 224 collapsed hips • 64.5% survival rate at a mean 4.3 years (range 2-12) • Relative risk of conversion to THA was associated with an increased lesion size and the amount of collapse

  22. Nonvacularized Bone Grafting • Provides decompression of the femoral head, removal of necrotic bone and structural support and scaffolding to allow repair and remodeling of subchondral bone • 3 distinct approaches • Core tract grafting • Femoral Neck Window - Light bulb procedure. • Trapdoor through articular cartilage of head

  23. Nonvacularized Bone Grafting Lieberman et al. 2002; 84:834-853

  24. Nonvacularized Bone Grafting Meyers et al; JBJS 1973:55A,pg 257

  25. Nonvacularized Bone Grafting • Rosenwasser et al. (ClinOrthop. 1994:306:17-27) • Described the “light bulb” approach • 87% success rate in a study of 15 hips with a mean F/U of 12 years • Mont et al. (ClinOrthop. 2003: 417:84-92) • 86% success rate in a study of 21 hips, light bulb approach • Harris score >80 and no additional procedures

  26. Nonvacularized Bone Grafting • Lieberman et al. (ClinOrthop 2004: 429:139-45) • Retrospective study, 17 hips, Core track method • Used bone morphogenic protein • 14/17 successful result • Harris score >80 and no conversion to THA

  27. Osteotomy • To remove necrotic or collapsing segment from the principle weight-bearing region • Replace this area with a segment of articular cartilage of the femoral head that is supported by healthy, viable bone • 2 Types: • Transtrochanteric Rotational Osteotomies • Intertrochantericvarus/valgusOsteotomies

  28. Rotational Osteotomy • Sugioka et al. • 78% of the 295 hips studied had a successful outcome at a mean of 11 year F/U • Masuda et al. • 69% of 52 hips studied had a successful outcome at a mean of 5 year F/U

  29. Rotational Osteotomy • Best results in young active patients who were not taking corticosteroids, had unilateral involvement with a good preoperative range of hip motion, and had a small lesion without femoral head collapse

  30. IntertrochantericOsteotomy • Less technically demanding • Commonly used in Europe with varying success

  31. IntertrochantericOsteotomy • Merle d’Aubigne et al. ((JBJS(br), 1965; 47:612-33) • Good to excellent pain reduction in 79% of the 75 hips with Ficat II or III. F/U 1 to 6 years. • Mont et al. (JBJS, 1996; 78:1032-38) • Good to excellent Harris hip scores in 76% of the 37 hips studied after treatment with varusosteotomy. F/U mean 11.5 years

  32. IntertochantericOsteotomy • Drescher et al. (JBJS (Br) 2003;85-B:969-74) • 70 intertrochanteric flexion osteotomies. • The mean follow-up was 10.4 years (3.0 to 20.3). • The overall mean Harris hip score increased from 51 points preoperatively to 71 points postoperatively. • A total of 19 hips (27%) underwent total hip arthroplasty at a mean of 8.7 years after osteotomy. • The five-year survival rate was 90%. • Flexion osteotomy is a safe and effective procedure in Ficat stage 2 and 3, preferably with a necrotic angle of <200°

  33. IntertochantericOsteotomy • The size of the osteonecrotic lesion was determined to be a critical factor in the rate of success of the osteotomy

  34. Management of Ficat I and II

  35. Summary • The etiology of ON of the hip may have a genetic basis • The interaction between certain risk factors and a genetic predisposition may determine the course of ON in a particular individual • The role of biological agents in altering the natural history of ON remains to be elucidated • Early diagnosis and intervention prior to collapse is key to successful outcomes of joint preserving procedures

More Related